APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short-acting Insulin

Compare research editions
View pricing & licenses

Selected research

Industry Research

Short-acting Insulin Industry Research Report 2026

28 December 2025122 pages

Choose your research edition.

Industry ResearchShort-acting Insulin Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Short-acting Insulin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Short-acting Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short-acting Insulin Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Short-acting Insulin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Short-acting Insulin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Short-acting Insulin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Short-acting Insulin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Short-acting Insulin include Zhuhai United Pharmaceutical, Wanbang Biopharmaceuticals, Sinovac Biotech, HTBT, Tonghua Dongbao Pharmaceutical, Wockhardt, Sanofi, Pfizer and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Short-acting Insulin market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Short-acting Insulin Market by Company

Zhuhai United Pharmaceutical

Wanbang Biopharmaceuticals

Sinovac Biotech

HTBT

Tonghua Dongbao Pharmaceutical

Wockhardt

Sanofi

Pfizer

Novo Nordisk

Eli Lilly

Biocon Biologics

Bayer

BASF

Abbott Laboratories

Short-acting Insulin Segment by Type

Regular Insulin

Biosynthetic Human Insulin

Recombinant Human Insulin

Other

Short-acting Insulin Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Gestational Diabetes

Complications of Diabetes

Other

Short-acting Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short-acting Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short-acting Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short-acting Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Short-acting Insulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Short-acting Insulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Short-acting Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Short-acting Insulin Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Short-acting Insulin Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Short-acting Insulin Sales Market Share by Manufacturers (2021-2026) Table 8. Global Short-acting Insulin Revenue of Manufacturers (2021-2026) Table 9. Global Short-acting Insulin Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Short-acting Insulin Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Short-acting Insulin Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Short-acting Insulin, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Short-acting Insulin, Product Type & Application Table 14. Global Short-acting Insulin Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Short-acting Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhuhai United Pharmaceutical Company Information Table 19. Zhuhai United Pharmaceutical Business Overview Table 20. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio Table 22. Zhuhai United Pharmaceutical Recent Developments Table 23. Wanbang Biopharmaceuticals Company Information Table 24. Wanbang Biopharmaceuticals Business Overview Table 25. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio Table 27. Wanbang Biopharmaceuticals Recent Developments Table 28. Sinovac Biotech Company Information Table 29. Sinovac Biotech Business Overview Table 30. Sinovac Biotech Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Sinovac Biotech Short-acting Insulin Product Portfolio Table 32. Sinovac Biotech Recent Developments Table 33. HTBT Company Information Table 34. HTBT Business Overview Table 35. HTBT Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. HTBT Short-acting Insulin Product Portfolio Table 37. HTBT Recent Developments Table 38. Tonghua Dongbao Pharmaceutical Company Information Table 39. Tonghua Dongbao Pharmaceutical Business Overview Table 40. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio Table 42. Tonghua Dongbao Pharmaceutical Recent Developments Table 43. Wockhardt Company Information Table 44. Wockhardt Business Overview Table 45. Wockhardt Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Wockhardt Short-acting Insulin Product Portfolio Table 47. Wockhardt Recent Developments Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sanofi Short-acting Insulin Product Portfolio Table 52. Sanofi Recent Developments Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Pfizer Short-acting Insulin Product Portfolio Table 57. Pfizer Recent Developments Table 58. Novo Nordisk Company Information Table 59. Novo Nordisk Business Overview Table 60. Novo Nordisk Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Novo Nordisk Short-acting Insulin Product Portfolio Table 62. Novo Nordisk Recent Developments Table 63. Eli Lilly Company Information Table 64. Eli Lilly Business Overview Table 65. Eli Lilly Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Eli Lilly Short-acting Insulin Product Portfolio Table 67. Eli Lilly Recent Developments Table 68. Biocon Biologics Company Information Table 69. Biocon Biologics Business Overview Table 70. Biocon Biologics Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Biocon Biologics Short-acting Insulin Product Portfolio Table 72. Biocon Biologics Recent Developments Table 73. Bayer Company Information Table 74. Bayer Business Overview Table 75. Bayer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bayer Short-acting Insulin Product Portfolio Table 77. Bayer Recent Developments Table 78. BASF Company Information Table 79. BASF Business Overview Table 80. BASF Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. BASF Short-acting Insulin Product Portfolio Table 82. BASF Recent Developments Table 83. Abbott Laboratories Company Information Table 84. Abbott Laboratories Business Overview Table 85. Abbott Laboratories Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Abbott Laboratories Short-acting Insulin Product Portfolio Table 87. Abbott Laboratories Recent Developments Table 88. Global Short-acting Insulin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Short-acting Insulin Sales by Region (2021-2026) & (K Units) Table 90. Global Short-acting Insulin Sales Market Share by Region (2021-2026) Table 91. Global Short-acting Insulin Sales by Region (2027-2032) & (K Units) Table 92. Global Short-acting Insulin Sales Market Share by Region (2027-2032) Table 93. Global Short-acting Insulin Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Short-acting Insulin Revenue Market Share by Region (2021-2026) Table 95. Global Short-acting Insulin Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Short-acting Insulin Revenue Market Share by Region (2027-2032) Table 97. North America Short-acting Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 99. North America Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 100. North America Short-acting Insulin Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Short-acting Insulin Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Short-acting Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 104. Europe Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 105. Europe Short-acting Insulin Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Short-acting Insulin Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Short-acting Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Short-acting Insulin Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Short-acting Insulin Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Short-acting Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 114. South America Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 115. South America Short-acting Insulin Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Short-acting Insulin Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Short-acting Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Short-acting Insulin Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Short-acting Insulin Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 123. Global Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 124. Global Short-acting Insulin Sales Market Share by Type (2021-2026) Table 125. Global Short-acting Insulin Sales Market Share by Type (2027-2032) Table 126. Global Short-acting Insulin Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Short-acting Insulin Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Short-acting Insulin Revenue Market Share by Type (2021-2026) Table 129. Global Short-acting Insulin Revenue Market Share by Type (2027-2032) Table 130. Global Short-acting Insulin Price by Type (2021-2026) & (US$/Unit) Table 131. Global Short-acting Insulin Price by Type (2027-2032) & (US$/Unit) Table 132. Global Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 133. Global Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 134. Global Short-acting Insulin Sales Market Share by Application (2021-2026) Table 135. Global Short-acting Insulin Sales Market Share by Application (2027-2032) Table 136. Global Short-acting Insulin Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Short-acting Insulin Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Short-acting Insulin Revenue Market Share by Application (2021-2026) Table 139. Global Short-acting Insulin Revenue Market Share by Application (2027-2032) Table 140. Global Short-acting Insulin Price by Application (2021-2026) & (US$/Unit) Table 141. Global Short-acting Insulin Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Short-acting Insulin Distributors List Table 145. Short-acting Insulin Customers List Table 146. Short-acting Insulin Industry Trends Table 147. Short-acting Insulin Industry Drivers Table 148. Short-acting Insulin Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Short-acting Insulin Product Image Figure 5. Global Short-acting Insulin Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Short-acting Insulin Market Size (2021-2032) & (US$ Million) Figure 7. Global Short-acting Insulin Sales (2021-2032) & (K Units) Figure 8. Global Short-acting Insulin Average Price (US$/Unit) & (2021-2032) Figure 9. Regular Insulin Product Image Figure 10. Biosynthetic Human Insulin Product Image Figure 11. Recombinant Human Insulin Product Image Figure 12. Other Product Image Figure 13. Type 2 Diabetes Product Image Figure 14. Type 1 Diabetes Product Image Figure 15. Gestational Diabetes Product Image Figure 16. Complications of Diabetes Product Image Figure 17. Other Product Image Figure 18. Global Short-acting Insulin Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Short-acting Insulin, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Short-acting Insulin Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Short-acting Insulin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Short-acting Insulin Sales by Region in 2025 Figure 24. Global Short-acting Insulin Revenue by Region in 2025 Figure 25. North America Short-acting Insulin Market Size by Country in 2025 Figure 26. North America Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 27. North America Short-acting Insulin Revenue Market Share by Country (2021-2032) Figure 28. United States Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Short-acting Insulin Market Size by Country in 2025 Figure 32. Europe Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 33. Europe Short-acting Insulin Revenue Market Share by Country (2021-2032) Figure 34. Germany Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Short-acting Insulin Market Size by Country in 2025 Figure 45. Asia Pacific Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Short-acting Insulin Revenue Market Share by Country (2021-2032) Figure 47. China Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Short-acting Insulin Market Size by Country in 2025 Figure 56. South America Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 57. South America Short-acting Insulin Revenue Market Share by Country (2021-2032) Figure 58. Brazil Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Short-acting Insulin Market Size by Country in 2025 Figure 62. Middle East and Africa Short-acting Insulin Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Short-acting Insulin Revenue Market Share by Country (2021-2032) Figure 64. Egypt Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Short-acting Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Short-acting Insulin Sales Market Share by Type (2021-2032) Figure 70. Global Short-acting Insulin Revenue Market Share by Type (2021-2032) Figure 71. Global Short-acting Insulin Price (US$/Unit) by Type (2021-2032) Figure 72. Global Short-acting Insulin Sales Market Share by Application (2021-2032) Figure 73. Global Short-acting Insulin Revenue Market Share by Application (2021-2032) Figure 74. Global Short-acting Insulin Price (US$/Unit) by Application (2021-2032) Figure 75. Short-acting Insulin Value Chain Figure 76. Short-acting Insulin Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Short-acting Insulin Industry Opportunities and Challenges

Scope & coverage.

Types
  • Regular Insulin
  • Biosynthetic Human Insulin
  • Recombinant Human Insulin
  • Other
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
  • Complications of Diabetes
  • Other
Companies covered
  • Zhuhai United Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Sinovac Biotech
  • HTBT
  • Tonghua Dongbao Pharmaceutical
  • Wockhardt
  • Sanofi
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Biocon Biologics
  • Bayer
  • BASF
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Short-acting Insulin Market Size (2021-2032)
  4. 2.2.2 Global Short-acting Insulin Sales (2021-2032)
  5. 2.2.3 Global Short-acting Insulin Market Average Price (2021-2032)
  6. 2.3 Short-acting Insulin by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Regular Insulin
  9. 2.3.3 Biosynthetic Human Insulin
  10. 2.3.4 Recombinant Human Insulin
  11. 2.3.5 Other
  12. 2.4 Short-acting Insulin by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Type 2 Diabetes
  15. 2.4.3 Type 1 Diabetes
  16. 2.4.4 Gestational Diabetes
  17. 2.4.5 Complications of Diabetes
  18. 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Short-acting Insulin Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Short-acting Insulin Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Short-acting Insulin Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Short-acting Insulin Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Short-acting Insulin Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Short-acting Insulin, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Short-acting Insulin, Product Type & Application
  8. 3.8 Global Manufacturers of Short-acting Insulin, Established Date
  9. 3.9 Global Short-acting Insulin Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhuhai United Pharmaceutical
  2. 4.1.1 Zhuhai United Pharmaceutical Company Information
  3. 4.1.2 Zhuhai United Pharmaceutical Business Overview
  4. 4.1.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio
  6. 4.1.5 Zhuhai United Pharmaceutical Recent Developments
  7. 4.2 Wanbang Biopharmaceuticals
  8. 4.2.1 Wanbang Biopharmaceuticals Company Information
  9. 4.2.2 Wanbang Biopharmaceuticals Business Overview
  10. 4.2.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio
  12. 4.2.5 Wanbang Biopharmaceuticals Recent Developments
  13. 4.3 Sinovac Biotech
  14. 4.3.1 Sinovac Biotech Company Information
  15. 4.3.2 Sinovac Biotech Business Overview
  16. 4.3.3 Sinovac Biotech Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sinovac Biotech Short-acting Insulin Product Portfolio
  18. 4.3.5 Sinovac Biotech Recent Developments
  19. 4.4 HTBT
  20. 4.4.1 HTBT Company Information
  21. 4.4.2 HTBT Business Overview
  22. 4.4.3 HTBT Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 HTBT Short-acting Insulin Product Portfolio
  24. 4.4.5 HTBT Recent Developments
  25. 4.5 Tonghua Dongbao Pharmaceutical
  26. 4.5.1 Tonghua Dongbao Pharmaceutical Company Information
  27. 4.5.2 Tonghua Dongbao Pharmaceutical Business Overview
  28. 4.5.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio
  30. 4.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
  31. 4.6 Wockhardt
  32. 4.6.1 Wockhardt Company Information
  33. 4.6.2 Wockhardt Business Overview
  34. 4.6.3 Wockhardt Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Wockhardt Short-acting Insulin Product Portfolio
  36. 4.6.5 Wockhardt Recent Developments
  37. 4.7 Sanofi
  38. 4.7.1 Sanofi Company Information
  39. 4.7.2 Sanofi Business Overview
  40. 4.7.3 Sanofi Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sanofi Short-acting Insulin Product Portfolio
  42. 4.7.5 Sanofi Recent Developments
  43. 4.8 Pfizer
  44. 4.8.1 Pfizer Company Information
  45. 4.8.2 Pfizer Business Overview
  46. 4.8.3 Pfizer Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Pfizer Short-acting Insulin Product Portfolio
  48. 4.8.5 Pfizer Recent Developments
  49. 4.9 Novo Nordisk
  50. 4.9.1 Novo Nordisk Company Information
  51. 4.9.2 Novo Nordisk Business Overview
  52. 4.9.3 Novo Nordisk Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Novo Nordisk Short-acting Insulin Product Portfolio
  54. 4.9.5 Novo Nordisk Recent Developments
  55. 4.10 Eli Lilly
  56. 4.10.1 Eli Lilly Company Information
  57. 4.10.2 Eli Lilly Business Overview
  58. 4.10.3 Eli Lilly Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Eli Lilly Short-acting Insulin Product Portfolio
  60. 4.10.5 Eli Lilly Recent Developments
  61. 4.11 Biocon Biologics
  62. 4.11.1 Biocon Biologics Company Information
  63. 4.11.2 Biocon Biologics Business Overview
  64. 4.11.3 Biocon Biologics Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Biocon Biologics Short-acting Insulin Product Portfolio
  66. 4.11.5 Biocon Biologics Recent Developments
  67. 4.12 Bayer
  68. 4.12.1 Bayer Company Information
  69. 4.12.2 Bayer Business Overview
  70. 4.12.3 Bayer Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Bayer Short-acting Insulin Product Portfolio
  72. 4.12.5 Bayer Recent Developments
  73. 4.13 BASF
  74. 4.13.1 BASF Company Information
  75. 4.13.2 BASF Business Overview
  76. 4.13.3 BASF Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 BASF Short-acting Insulin Product Portfolio
  78. 4.13.5 BASF Recent Developments
  79. 4.14 Abbott Laboratories
  80. 4.14.1 Abbott Laboratories Company Information
  81. 4.14.2 Abbott Laboratories Business Overview
  82. 4.14.3 Abbott Laboratories Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Abbott Laboratories Short-acting Insulin Product Portfolio
  84. 4.14.5 Abbott Laboratories Recent Developments
5 Global Short-acting Insulin Market Scenario by Region
  1. 5.1 Global Short-acting Insulin Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Short-acting Insulin Sales by Region: 2021-2032
  3. 5.2.1 Global Short-acting Insulin Sales by Region: 2021-2026
  4. 5.2.2 Global Short-acting Insulin Sales by Region: 2027-2032
  5. 5.3 Global Short-acting Insulin Revenue by Region: 2021-2032
  6. 5.3.1 Global Short-acting Insulin Revenue by Region: 2021-2026
  7. 5.3.2 Global Short-acting Insulin Revenue by Region: 2027-2032
  8. 5.4 North America Short-acting Insulin Market Facts & Figures by Country
  9. 5.4.1 North America Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Short-acting Insulin Sales by Country (2021-2032)
  11. 5.4.3 North America Short-acting Insulin Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Short-acting Insulin Market Facts & Figures by Country
  16. 5.5.1 Europe Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Short-acting Insulin Sales by Country (2021-2032)
  18. 5.5.3 Europe Short-acting Insulin Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Short-acting Insulin Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Short-acting Insulin Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Short-acting Insulin Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Short-acting Insulin Market Facts & Figures by Country
  41. 5.7.1 South America Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Short-acting Insulin Sales by Country (2021-2032)
  43. 5.7.3 South America Short-acting Insulin Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Short-acting Insulin Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Short-acting Insulin Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Short-acting Insulin Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Short-acting Insulin Sales by Type (2021-2032)
  2. 6.1.1 Global Short-acting Insulin Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Short-acting Insulin Sales Market Share by Type (2021-2032)
  4. 6.2 Global Short-acting Insulin Revenue by Type (2021-2032)
  5. 6.2.1 Global Short-acting Insulin Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Short-acting Insulin Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Short-acting Insulin Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Short-acting Insulin Sales by Application (2021-2032)
  2. 7.1.1 Global Short-acting Insulin Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Short-acting Insulin Sales Market Share by Application (2021-2032)
  4. 7.2 Global Short-acting Insulin Revenue by Application (2021-2032)
  5. 7.2.1 Global Short-acting Insulin Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Short-acting Insulin Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Short-acting Insulin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Short-acting Insulin Value Chain Analysis
  2. 8.1.1 Short-acting Insulin Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Short-acting Insulin Production Mode & Process
  5. 8.2 Short-acting Insulin Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Short-acting Insulin Distributors
  8. 8.2.3 Short-acting Insulin Customers
9 Global Short-acting Insulin Analyzing Market Dynamics
  1. 9.1 Short-acting Insulin Industry Trends
  2. 9.2 Short-acting Insulin Industry Drivers
  3. 9.3 Short-acting Insulin Industry Opportunities and Challenges
  4. 9.4 Short-acting Insulin Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst